AUDIO – Generics not done merging

November 13, 2007

downey2.jpgBarr acquired Pliva. Teva gobbled up Ivax. Watson ate Andrx.

But the generic drug industry is not done consolidating, according to Barr Pharmaceuticals CEO Bruce Downey.

Aside from the top players in the industry, a second tier of generic drug companies could be the next acquisition targets, he told the Health Summit in a phone interview.

No comments so far

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see